DNA plasmid manufacturer VGXI Inc. filed suit against a Chinese biotechnology company alleging the company stole proprietary technology through its collaboration with another drugmaker. 

The suit is the most recent development in VGXI’s ongoing dispute with Pennsylvania-based Inovio, a company that had sought to obtain the DNA company’s technology in 2020 to develop a COVID-19 vaccine, an effort that was ultimately unsuccessful.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]